Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An acute myeloid leukemia characterized by a predominant immature erythroid population. There are two subtypes recognized: erythroleukemia and pure erythroid leukemia. (WHO, 2001)
Features include common findings: Low blood cell counts (all types) (pancytopenia), Low white blood cell count (decreased total leukocyte count), Low red blood cell count (anemia), and Refractory anemia with ringed sideroblasts and others; and sometimes findings: Bone marrow hypocellularity.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 4 | Low blood cell counts (all types) (pancytopenia), Low white blood cell count (decreased total leukocyte count), Low red blood cell count (anemia) |
Biomarker and diagnostic research for acute erythroid leukemia has been reported in the published literature.
Phenotype severity distribution: 8 common features.
Estimated prevalence: Unknown (Unknown prevalence).
3 clinical trials registered. Interventions under study include drug therapy, other interventions, and gene therapy. Pipeline includes 1 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
111 publications have been identified in PubMed for acute erythroid leukemia. Research spans Basic Science / Preclinical (46%), Gene Therapy / Novel Therapeutics (22%), and Case Report / Case Series (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 51 |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 3:44 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about acute erythroid leukemia
Bones and joints | 2 | Bone marrow hypercellularity, Bone marrow hypocellularity |
Lab test results | 1 | Monoclonal immunoglobulin M proteinemia |
New treatment approaches | 24 | 22% |
Patient case studies | 19 | 17% |
Research summaries | 7 | 6% |
Disease patterns and progression | 5 | 5% |
Clinical study results | 3 | 3% |
Testing and diagnosis research | 2 | 2% |
Liu X (2026). [PMID: 41749043](https://pubmed.ncbi.nlm.nih.gov/41749043/). *Analytical chemistry*. [Basic Science / Preclinical]
Yang M (2026). [PMID: 41881955](https://pubmed.ncbi.nlm.nih.gov/41881955/). *Cell Death Dis*. [Basic Science / Preclinical]
Prajapati S (2026). [PMID: 41615563](https://pubmed.ncbi.nlm.nih.gov/41615563/). *Blood research*. [Review / Meta-Analysis]
Desoky AE (2026). [PMID: 41764642](https://pubmed.ncbi.nlm.nih.gov/41764642/). *Journal of the Association of Genetic Technologists*. [Review / Meta-Analysis]
Naji NS (2026). [PMID: 40874324](https://pubmed.ncbi.nlm.nih.gov/40874324/). *Haematologica*. [Gene Therapy / Novel Therapeutics]
Zhao SS (2026). [PMID: 42103652](https://pubmed.ncbi.nlm.nih.gov/42103652/). *Zhonghua Nei Ke Za Zhi*. [Diagnostic / Biomarker]
Ma W (2026). [PMID: 41263466](https://pubmed.ncbi.nlm.nih.gov/41263466/). *Turkish journal of haematology : official journal of Turkish Society of Haematology*. [Gene Therapy / Novel Therapeutics]
Brunetti M (2026). [PMID: 42158426](https://pubmed.ncbi.nlm.nih.gov/42158426/). *Front Oncol*. [Basic Science / Preclinical]
Yang Z (2026). [PMID: 41485687](https://pubmed.ncbi.nlm.nih.gov/41485687/). *Fitoterapia*. [Gene Therapy / Novel Therapeutics]
Zhao Y (2026). [PMID: 42205757](https://pubmed.ncbi.nlm.nih.gov/42205757/). *Front Oncol*. [Case Report / Case Series]